| Metric | Q2 FY27 | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue from operations | 476.6 | 422.3 | 555.6 |
| Other income | 12.4 | 12.2 | 15.6 |
| Total income | 489.1 | 434.5 | 571.2 |
| Profit before exceptional items & tax | -10.8 | -42.9 | 83.8 |
| Profit before tax | -10.8 | -42.9 | 83.8 |
| Net profit | 2.3 | -45.2 | 66.4 |
| Operating margin | -2.2% | -9.9% | 14.7% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -96.50% |
|---|---|
| Revenue, year on year | -14.20% |
| Operating profit, year on year | -134.00% |
| Operating profit, quarter on quarter | +57.90% |
NSE results filing, NSE: COHANCE. Figures extracted from the filing.
Cohance Lifesciences Ltd: key numbers
- Share price
- ₹433.00
- Market cap
- ₹16,566 Cr
- Revenue (annual)
- ₹2,269 Cr
- Net profit (annual)
- ₹179.2 Cr
- P/E (TTM)
- 155.9×Sector 42.0×
- Promoter holding
- 57.48%-0.01% QoQ
- FII holding
- 7.71%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Cohance Lifesciences Ltd
All →Cohance Lifesciences Management Change
Cohance Lifesciences appointed Kuber Jagdale as Executive Director for 60 months, effective 7 November 2026. He brings over three decades of pharmaceutical manufacturing and operations experience.
Cohance Lifesciences Earnings Call Transcript: Key Takeaways
Q2 revenue rose about 13% QoQ to ₹477 Cr and adjusted EBITDA reached about ₹46 Cr (~10% margin), but both remain below last year. H2 YoY growth is promised without figures, and FY27 specialty chemicals guidance was cut to decline.
Cohance Lifesciences Results Update
Cohance Lifesciences issued a press release on its unaudited Q2 and H1 FY27 results. It reported lower year-on-year revenue and an expected stronger second half.
Cohance Lifesciences Investor Presentation: Key Takeaways
Q2FY27 revenue INR 4,766 Mn, down 14.2% YoY but up 12.9% QoQ. Adjusted EBITDA margin 9.6%, adjusted PAT INR 74 Mn back positive. Strategy centres on One Cohance integration and H2 recovery.
Cohance Lifesciences Adverse Business Impact
Cohance Lifesciences disclosed a TGPCB closure order halting manufacturing at its Suryapet site after an industrial accident. The financial impact cannot yet be quantified.
Cohance Lifesciences Board Meeting Date
Cohance Lifesciences will hold a board meeting on 6 November 2026 to approve Q2 and half-year results. The trading window stays closed until 9 November 2026.